Company Performance - Hawkins reported quarterly earnings of $0.78 per share, exceeding the Zacks Consensus Estimate of $0.74 per share, and up from $0.66 per share a year ago, representing an earnings surprise of 5.41% [1] - The company posted revenues of $245.32 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.62%, compared to $223.02 million in the same quarter last year [2] - Over the last four quarters, Hawkins has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Future Outlook - The sustainability of Hawkins' stock price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.34 on revenues of $268.31 million, and for the current fiscal year, it is $4.54 on revenues of $1.05 billion [7] - The estimate revisions trend for Hawkins is currently favorable, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Chemical - Specialty industry, to which Hawkins belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can materially affect stock performance [5][8]

Steris (STE) came out with quarterly earnings of $2.74 per share, beating the Zacks Consensus Estimate of $2.59 per share. This compares to earnings of $2.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.79%. A quarter ago, it was expected that this medical products maker would post earnings of $2.32 per share when it actually produced earnings of $2.32, delivering no surprise.Over the last four quarters, the company has s ...

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced earnings of $0.52, delivering a surprise of 1,400%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.ARS Pharmaceuticals, Inc., whi ...

Kolibri Global Energy Inc. (KGEI) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.08%. A quarter ago, it was expected that this company would post earnings of $0.14 per share when it actually produced earnings of $0.16, delivering a surprise of 14.29%.Over the last four quarters, t ...

Company Performance - M-tron Industries, Inc. reported quarterly earnings of $0.56 per share, missing the Zacks Consensus Estimate of $0.66 per share, but showing an increase from $0.53 per share a year ago, resulting in an earnings surprise of -15.15% [1] - The company posted revenues of $12.73 million for the quarter ended March 2025, which was 2.06% below the Zacks Consensus Estimate, but an increase from $11.19 million year-over-year [2] - Over the last four quarters, M-tron Industries has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - M-tron Industries shares have increased approximately 18.5% since the beginning of the year, contrasting with a -0.6% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.66 on revenues of $13.2 million, and for the current fiscal year, it is $2.72 on revenues of $53.7 million [7] Industry Outlook - The Engineering - R and D Services industry, to which M-tron Industries belongs, is currently ranked in the top 9% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact M-tron Industries' stock performance [5][6]

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -46.67%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.20, delivering a surprise of -33.33%.Over the last four quarters, the company has ...

Company Performance - Eton Pharmaceuticals reported quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share, compared to a loss of $0.03 per share a year ago, representing an earnings surprise of -22.22% [1] - The company posted revenues of $17.28 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.71%, and this is an increase from year-ago revenues of $7.97 million [2] - Over the last four quarters, Eton Pharmaceuticals has surpassed consensus revenue estimates three times [2] Stock Performance - Eton Pharmaceuticals shares have increased approximately 30.3% since the beginning of the year, while the S&P 500 has declined by -0.6% [3] - The current consensus EPS estimate for the coming quarter is $0.07 on revenues of $16.7 million, and for the current fiscal year, it is $0.53 on revenues of $75.35 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Eton Pharmaceuticals belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 71.43%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.39 per share when it actually produced a loss of $0.67, delivering a surprise of -71.79%.Over the last four quart ...

Company Performance - Biodesix, Inc. reported a quarterly loss of $0.08 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.14 per share a year ago [1] - The company posted revenues of $17.96 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 7.19%, but showing an increase from $14.82 million year-over-year [2] - Over the last four quarters, Biodesix has surpassed consensus EPS estimates three times, while it has topped consensus revenue estimates only once [2][3] Stock Performance - Biodesix shares have declined approximately 76.5% since the beginning of the year, contrasting with the S&P 500's decline of only 0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $22.3 million, and for the current fiscal year, it is -$0.22 on revenues of $92.75 million [7] Industry Outlook - The Medical Services industry, to which Biodesix belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Biodesix's stock performance [5][6]

Group 1 - Lexicon Pharmaceuticals reported a quarterly loss of $0.07 per share, better than the Zacks Consensus Estimate of a loss of $0.10, and an improvement from a loss of $0.20 per share a year ago, resulting in an earnings surprise of 30% [1] - The company posted revenues of $1.26 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 23.52%, compared to year-ago revenues of $1.13 million [2] - Lexicon shares have declined approximately 8.8% since the beginning of the year, while the S&P 500 has seen a decline of -0.6% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $2.37 million, and for the current fiscal year, it is -$0.37 on revenues of $15.43 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 35% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Lexicon has a Zacks Rank of 2 (Buy), suggesting that the stock is expected to outperform the market in the near future [6]